Morgan Stanley Discount Zert NOVN.../ DE000MG2YJF3 /
16/05/2024 17:42:48 | Chg.- | Bid10:26:59 | Ask10:26:59 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
85.84EUR | - | 86.09 Bid Size: 5,000 |
86.10 Ask Size: 5,000 |
NOVARTIS N | - CHF | 30/12/2025 | Call |
GlobeNewswire
16/05
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional...
GlobeNewswire
16/05
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 f...
GlobeNewswire
16/04
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
14/03
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
10/01
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
05/01
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire
02/01
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
19/12/2023
Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire
11/12/2023
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire
08/12/2023
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire
06/12/2023
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
GlobeNewswire
20/11/2023
Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
GlobeNewswire
19/10/2023
Fairway Consulting Group Appoints Matthew Perry as Vice President of Executive Search